second
part
twopart
review
absorpt
deliveri
peptid
protein
drug
via
nonparenter
rout
discuss
approach
consid
includ
absorpt
enhanc
iontophoret
method
use
absorpt
inhibitor
prodrug
possibl
nonparenter
administr
rout
deliveri
peptid
protein
drug
includ
nasal
buccal
rectal
vagin
transderm
ocular
oral
rout
absenc
absorpt
enhanc
rout
generahi
much
less
efficaci
parenter
administr
exampl
oral
administr
lhrh
requir
dose
higher
parenter
rout
effect
dose
lhrh
via
rout
rel
parenter
rout
lootim
nasal
li
wan
po
drug
deliveri
research
group
school
pharmaci
queen
univers
belfast
lisbum
road
belfast
uk
time
rectal
vagin
higher
sandow
petri
oral
rout
far
popular
rout
drug
administr
number
studi
carri
attempt
deliv
peptid
protein
drug
effect
circul
four
problem
mention
earlier
must
overcom
effici
deliveri
drug
acidcatalyz
degrad
stomach
ii
proteolyt
breakdown
gastrointestin
tract
iii
poor
permeabl
across
gastrointestin
mucosa
iv
firstpass
metabol
transfer
across
absorpt
barrier
liver
tabl
show
absorpt
oral
administ
peptid
protein
drug
molecular
weight
captopril
enalapril
rel
higher
bioavail
tabl
due
low
molecular
weight
abil
inhibit
tissu
rbolpeptidas
cyclosporin
cyclic
peptid
number
methyl
amino
acid
residu
resist
enzym
hydrolysi
henc
good
bioavail
proteas
inhibitor
absorpt
enhanc
coadminist
peptid
drug
enhanc
oral
absorpt
good
exampl
oral
argininevasopressin
produc
reduct
urin
flow
rat
oral
dose
pmol
requir
drug
coadminist
aprotinin
proteas
inhibitor
oral
dose
reduc
pmol
saffran
et
al
peptid
protein
drug
despit
use
mani
kind
enhanc
bioavail
still
inadequ
instanc
bioavail
human
recombi
nant
found
less
increas
absorpt
enhanc
investig
paulesu
et
al
ingest
peptid
protein
undergo
attack
pepsin
stomach
follow
hydrolysi
mainli
action
brush
border
peptidas
small
peptid
dipeptid
tripeptid
produc
undergo
hydrolysi
cytoplasm
brush
border
intestin
enzym
peptidas
found
intestin
mucosa
includ
leucin
aminopeptidas
ec
aminopeptidas
aminopolypeptidas
ec
aminotripeptidas
ec
angiotensinas
ec
glycylglycinedipeptidas
deaminopeptidas
ec
serin
carboxypeptidas
ec
dipeptidas
lower
specif
tripeptidas
prolidas
ganapathi
et
al
carboxypeptidas
appel
besid
peptidas
also
proteinas
intestin
pore
radiu
intestin
mucosa
limit
factor
peptid
transport
equival
pore
radiu
intestin
mucosa
rat
found
lindemann
solomon
valu
confirm
smyth
wright
amino
acid
dipeptid
tripeptid
therefor
abl
penetr
intestin
wall
larg
peptid
hinder
pore
radiu
mucosa
found
revers
enlarg
absorpt
enhanc
sodium
chdate
hirai
et
al
ziv
et
al
number
studi
demonstr
peptid
absorb
activ
transport
via
specif
peptidemedi
carrier
system
rubino
et
al
addison
et
al
addison
et
al
sigristnelson
berteloot
et
al
berteloot
et
al
ganapathi
et
al
ganapathi
et
al
b
cheeseman
johnston
peptid
absorb
carriermedi
transport
system
obvious
subject
competit
stctural
similar
peptid
proton
gradient
gener
maintain
nah
exchang
brushbord
membran
respons
inward
na
gradient
ganapathi
radhakrishan
nakatpas
system
activ
pump
naf
cell
process
lower
intracellular
concentr
naf
consequ
result
inward
proton
gradient
across
brushbord
membran
ganapathi
leibach
recent
intestin
transport
ace
inhibitor
captopril
shown
mediat
activ
carrier
system
fhu
amidon
transport
captopril
shown
sodiumdepend
two
structur
similar
peptid
glycylprolin
acetylprolin
shown
interfer
absorpt
harmalin
specif
inhibitor
atpas
reduc
uptak
captopril
intestin
rout
zhou
li
wan
po
antihypertens
peptid
agent
lisinopril
also
found
transport
activ
absorpt
mechan
friedman
et
al
similar
activ
carriermedi
system
appear
identifi
tissu
rectal
buccal
nasal
ocular
tissu
oral
protein
deliveri
system
investig
includ
sphere
coat
crosslink
polymer
coat
biodegrad
microspher
saffran
group
exampl
report
promis
result
use
crosslink
coat
administ
insulin
peptid
oral
peptid
drug
coat
polym
crosslink
azoaromat
group
form
impervi
protect
film
resist
enzymat
hydrolysi
upper
gastrointestin
tract
coat
drug
reach
larg
intestin
endogen
microflora
degrad
polym
film
drug
releas
lumen
colon
absorpt
studi
signific
drop
blood
glucos
level
observ
coat
particl
may
take
form
nanocapsul
nanocapsul
use
deliv
cytostat
drug
vivo
cancer
model
nanocapsul
shown
prolong
absorpt
lipophil
drug
intestin
mucosa
recent
polyalkylcyanoacryl
nanocapsul
use
potenti
insulin
carrier
signific
prolong
hoglycaemia
observ
demg
et
al
demg
et
al
subcutan
administr
nanocapsul
decreas
blood
glucos
level
induc
low
glucos
level
maintain
h
drop
glucos
level
observ
subcutan
administr
control
formul
effect
complet
disappear
h
inject
intragastr
administr
encapsul
insulin
decreas
glucos
level
found
second
ninth
day
control
valu
reach
day
recent
work
demg
et
al
decreas
glycemia
observ
second
day
oral
administr
insulin
nanocapsul
iukg
effect
maintain
day
iukg
respect
normal
rat
hyperglycaemia
induc
oral
glucos
load
reduc
dose
oral
insulin
nanocapsul
demg
et
al
nasal
dehveri
peptid
protein
review
sever
author
sandow
patri
harri
su
system
defiveri
protein
peptid
drug
nasal
rout
appear
effici
compar
rout
administr
lhrh
agonist
via
nasal
rout
may
requir
loofold
increas
dose
achiev
compar
level
parenter
rout
nevertheless
effici
rectal
vagin
rout
oral
bioavail
lhrh
extrem
low
requir
higher
dose
requir
nasal
rout
sandow
petri
polypeptid
drug
oxytocin
patocon
sytocinon
nineaminoacid
peptid
vasopressin
postacton
desmopressin
minirin
ddavp
lhrh
analogu
buserelin
routin
given
nasal
rout
harri
tabl
list
report
bioavail
molecular
weight
peptid
protein
drug
follow
nasal
administr
intranas
deliveri
insulin
extens
studi
hirai
et
al
b
mose
et
al
mishima
et
al
aungst
roger
aungst
et
al
transnas
permeabl
intranas
absorpt
found
significantli
enhanc
differ
type
enhanc
includ
bile
acid
yokosuka
et
al
hirai
et
al
b
mose
et
al
mose
et
al
mishima
et
al
aungst
roger
aungst
et
al
fatti
acid
mishima
et
al
ester
hirai
et
al
ether
hirai
et
al
glycosid
hirai
et
al
lipopeptid
hirai
et
al
enhanc
also
use
promot
uptak
peptid
protein
drug
intranas
rout
exampl
hgh
daugherti
et
al
glycochol
glucagon
pontiroli
et
al
pontiroli
et
al
sodium
lauryl
sulphat
calcitonin
hanson
et
al
tabl
anoth
enhanc
use
insulin
stdhf
sodium
taurodihydrofusid
rel
low
membran
lytic
activ
longeneck
et
al
deurloo
et
al
intranas
deliveri
interferon
localis
effect
anoth
area
investig
exampl
number
studi
demonstr
prophylact
antivir
efficaci
rembin
human
ifn
incid
sever
respiratori
viru
infect
includ
caus
common
cold
significantli
reduc
intranas
administr
interferonp
higgin
et
al
turner
et
al
recombin
also
intranas
prophylact
efficaci
protect
volunt
infect
intranas
challeng
rhinoviru
higgin
et
al
intranas
deliveri
also
investig
administr
vaccin
tabl
intranas
deliveri
peptid
protein
drug
attract
sever
reason
nasal
mucosa
appear
less
proteolyt
activ
gastrointestin
tract
parr
zhou
li
wan
po
firstpass
hepat
metabol
sabin
et
al
karzon
kumlien
et
al
wright
et
al
bypass
absorpt
system
circul
occur
rel
rapidli
intranas
administr
may
result
consist
absorpt
drug
propranolol
variabl
oral
bioavailabili
hussain
et
al
surfac
area
highli
vascular
nasal
mucosa
extens
due
subdivis
nasal
passag
turbin
sinus
numer
microvilli
mucos
cell
parr
propos
mechan
drug
absorb
nasal
mucosa
includ
passiv
diffus
facilit
activ
transport
parr
paracellular
transport
intracellular
channel
water
influx
morimoto
et
al
possibl
rout
absorpt
nose
review
chien
chang
exampl
amino
acid
includ
arginin
glutam
acid
glycin
prolin
serin
yaminobutyr
acid
shown
absorb
nasal
mucosa
blood
vessel
via
activ
transport
system
absorpt
rout
peptid
drug
penicillin
found
across
nasal
mucosa
bloodstream
protein
includ
egg
albumin
serum
albumin
howev
transport
nasal
mucosa
lymphat
system
chien
chang
enzym
within
nasal
tissu
act
barrier
peptid
absorpt
includ
leucin
aminopeptidas
significantli
reduc
bioavail
peptideprotein
drug
chien
chang
methionin
enkephalin
dodda
kashi
leucin
enkephalin
dodda
kashi
substanc
p
lee
insulin
proinsulin
lee
among
peptid
protein
drug
found
hydrolyz
nasal
proteas
polypeptid
drug
methionin
enkephalin
substanc
p
found
readili
hydrolys
nasal
homogen
drug
insulin
proinsulin
tabl
insulin
found
mainli
degrad
leucin
aminopeptidas
smith
et
al
would
suggest
number
yet
unidentifi
proteol
enzym
ieucin
aminopeptidas
involv
hydra
lysi
methionin
enkephalin
substanc
p
data
list
tabl
summaris
suscept
differ
peptid
protein
drug
nasal
proteas
rel
resist
leucin
enkephalin
nasal
proteas
worth
note
chemic
modif
peptid
drug
therefor
like
use
approach
enhanc
absorpt
may
also
explain
larger
peptid
drug
secretin
higher
bioavail
smaller
peptid
drug
like
oxytocin
lhrh
agonist
tabl
although
nasal
proteolyt
barrier
significantli
reduc
bioavail
peptid
protein
drug
level
aminopeptidas
present
may
much
lower
nasal
tissu
gastrointestin
tissu
zhou
li
wan
po
po
microspher
present
potenti
control
releas
system
nasal
peptid
drug
deliveri
illum
microspher
drugload
degrad
starch
microspher
dsm
diamet
um
recent
studi
bjork
edman
insulin
njkg
dsm
prepar
administ
nasal
dri
powder
result
dosedepend
decreas
blood
glucos
rat
bioavail
nasal
insulin
found
wherea
effect
dsm
alon
solubl
insulin
produc
effect
degrad
starch
microspher
therefor
offer
possibl
avenu
investig
nasal
administr
peptid
protein
drug
rectal
deliveri
peptid
protein
drug
anoth
activ
area
research
rectal
deliveri
offer
mani
advantag
includ
avoid
drug
dilut
prior
reach
system
circul
drug
contact
digest
fluid
consequenti
degrad
drug
absorpt
interrupt
case
accident
overdos
drug
reaction
extent
breakdown
polypeptid
low
lower
digest
tract
rel
small
intestin
stomach
due
low
enzymat
activ
neutral
ph
howev
morimoto
et
al
yagi
et
al
caprat
cmc
na
di
murakami
et
al
salicyl
moor
et
al
adult
lower
intestin
shown
rel
imperm
uptak
macromolecul
warshaw
et
al
warshaw
et
al
taniguchi
et
al
bovin
serum
albumin
heparin
protein
drug
high
molecular
weight
report
peptid
protein
drug
deliv
rectal
rout
includ
insulin
ziv
et
al
kim
et
al
morimoto
et
al
aungst
roger
aungst
et
al
calcitonin
morimoto
et
al
gastrin
pentagastrin
yoshioka
et
al
human
growth
hormon
moor
et
al
vasopressin
saffran
et
al
tabl
show
rectal
bioavail
peptid
protein
drug
rectal
tissu
known
contain
number
proteolyt
enzym
includ
enkephalinas
grimaud
et
al
proteas
burtin
et
al
cathepsin
b
cathepsin
h
collagenaselik
peptidas
durdey
et
al
proteaselik
peptidas
gelist
et
al
plasminogen
activ
gelist
et
al
harvey
et
al
urokinas
gelist
et
al
data
tabl
show
activ
proteolyt
enzym
rectal
tissu
similar
nasal
tissu
bioavail
peptid
drug
insulin
ishida
et
al
nagai
nagai
nagai
machida
protirelin
trh
analogu
buserelin
lhrh
analogu
merkl
et
al
buccal
rout
gener
poor
aungst
cowork
compar
efficaci
insulin
administ
nasal
rectal
buccal
sublingu
intramuscular
rout
effect
bile
salt
absorpt
promot
found
rank
order
extent
absorpt
nasal
rectal
buccal
sublingu
sodium
glycochol
coadministr
rectal
nasal
insulin
approxim
equipot
buccal
insulin
slightli
less
effect
howev
demonstr
robinson
buccal
rout
use
success
deliveri
peptid
probe
tripeptid
molecular
mass
da
anoth
peptid
drug
success
administ
sublingu
rout
captopril
treatment
acut
hertens
haugerkleven
castillo
et
al
buccal
tissu
found
contain
mani
enzym
includ
proteolyt
enzym
tabl
list
proteolyt
activ
buccal
tissu
rel
other
seen
methionin
enkephalin
substanc
p
highli
suscept
enzym
insulin
proinsulin
much
less
affect
ocular
deliveri
drug
typic
treatment
ocular
inflamm
wound
glaucoma
rout
also
investig
system
deliveri
peptid
protein
drug
christi
hanzal
demonstr
topic
ocular
administr
insulin
produc
sustain
lower
blood
glucos
proport
dose
instil
effect
ocular
dose
compar
dose
administ
subcutan
sinc
mani
attempt
made
improv
bioavail
topic
ocular
drug
date
minor
improv
achiev
recent
claim
painless
simpl
practic
method
design
system
deliveri
insulin
ocular
rout
chiou
chuang
although
longterm
efficaci
safeti
yet
defin
saponin
glycosid
found
best
enhanc
insulin
absorpt
via
rout
tween
least
effect
efficaci
order
seven
compound
studi
follow
saponin
fusid
acid
polyoxyethylen
ether
edta
glycochol
decamethonium
tween
bioenhanc
therefor
like
increasingli
import
ocular
administr
peptid
protein
drug
topic
ocular
drug
deliveri
use
convent
dosag
form
solut
suspens
ointment
rel
ineffici
less
appli
dose
deliv
across
cornea
eye
lee
low
absorpt
caus
lipophil
epithelium
dilut
drug
tear
bind
drug
protein
tear
subsequ
loss
nasal
passag
besid
diffus
barrier
enzym
barrier
also
play
import
role
mani
enzym
found
ocular
tissu
hard
crabb
mauric
transport
administ
peptid
protein
drug
across
ocular
barrier
mainli
limit
proteinas
neutral
proteas
aminopeptidas
exampl
within
min
instil
solut
leucin
methionin
enkephalin
found
hydrolyz
epithelium
rabbit
proteolyt
activ
tissu
found
highest
among
seven
tissu
test
use
methionin
enkephalin
substrat
tabl
dodda
kashi
lee
b
therefor
despit
possibl
achiev
system
absorpt
peptid
topic
appli
ophthalm
solut
much
work
still
requir
make
practic
realiti
enzym
activ
ocular
tissu
control
absorpt
enhanc
care
select
due
high
sensit
eye
irrit
extern
appli
substanc
sever
advantag
rout
provid
drug
absorb
suffici
quantiti
exert
system
effect
use
rout
possibl
avoid
hepat
firstpass
metabol
gastrointestin
breakdown
drug
ii
provid
control
administr
iii
reduc
frequenc
dose
iv
improv
patient
complianc
v
permit
rel
abrupt
termin
drug
effect
remov
deliveri
system
skin
surfac
fact
polypeptid
protein
drug
polar
compound
high
molecular
weight
therefor
diffus
poorli
across
stratum
corneum
howev
recent
potent
neuropeptid
desenkephalinpendorphin
depe
report
success
deliv
transderm
across
intact
human
skin
cultur
human
skin
cell
boddc
et
al
skin
adhes
hydrogel
film
appear
provid
effect
method
deliveri
peptid
boddc
et
al
techniqu
iontophoresi
siddiqui
et
al
howev
larg
hydrophil
peptid
may
administ
dermal
rout
iontophoresi
ion
charg
molecul
transport
across
skin
use
electr
current
mani
studi
report
encourag
result
transderm
transport
insulin
use
techniqu
rolf
siddiqui
et
al
liu
et
al
srinivasan
et
al
thyrotropinreleas
hormon
also
report
partial
deliv
techniqu
burnett
marrero
tabl
rate
transderm
iontophoret
deliveri
peptid
protein
drug
report
depend
ph
ionic
strength
electrolyt
concentr
formul
well
appli
voltag
skin
low
proteolyt
activ
low
content
solubl
protein
zhou
li
wan
po
po
use
lleucinepnaphthylamid
substrat
activ
leucin
aminopeptidas
found
lowest
rat
skin
among
five
tissu
homogen
use
intestin
buccal
nasal
rectal
dermal
tissu
low
skin
permeabl
like
main
limit
factor
peptid
protein
drug
absorpt
transderm
rout
increas
number
peptid
protein
drug
like
introduc
therapeut
forthcom
year
potenti
use
much
enhanc
constraint
impos
parenter
rout
deliveri
use
overcom
studi
result
review
far
suggest
use
absorpt
enhanc
specialis
deliveri
system
proteas
inhibitor
may
improv
deliveri
agent
system
circul
unlik
one
approach
would
enabl
control
deliveri
peptid
protein
drug
singl
system
go
univers
applic
agent
would
benefit
tailor
deliveri
system
inde
literatur
review
also
suggest
portal
entri
may
prefer
other
specif
peptid
molecular
modif
introduc
resist
peptidas
proteas
also
add
method
avail
improv
absorpt
peptid
protein
drug
specialis
drug
deliveri
system
far
yield
limit
improv
nasal
rout
appear
use
practic
altern
far
despit
confid
predict
problem
peptid
protein
drug
deliveri
like
continu
challeng
pharmaceut
scientist
mani
year
come
adibi
sa
mors
el
number
glycin
residu
limit
intact
absorpt
glycin
oligopeptid
human
jejunum
j
clin
invest
allen
jg
hava
l
leicht
e
lenoxsmith
j
nisbet
lj
phosphonopeptid
antibacteri
agent
metabol
pharmacokinet
alafosfalin
anim
human
antimicrob
agent
chemoth
